Podcast 294: PD-1 blockade in locally advanced rectal cancer

NEJM Journal Watch Podcasts: Clinical Conversations

Contenuto fornito da NEJM Group. Tutti i contenuti dei podcast, inclusi episodi, grafica e descrizioni dei podcast, vengono caricati e forniti direttamente da NEJM Group o dal partner della piattaforma podcast. Se ritieni che qualcuno stia utilizzando la tua opera protetta da copyright senza la tua autorizzazione, puoi seguire la procedura descritta qui https://it.player.fm/legal.

2y ago 13:08

MP3•Pagina principale dell'episodio

Locally advanced rectal cancer usually receives a three-part treatment: chemotherapy followed by radiotherapy and then surgery.

In a small-cohort study presented at this year’s ASCO conference researchers used a PD-1 inhibitor — dostarlimab — every three weeks for 6 months against the disease. All patients had mismatch repair deficient tumors. No other treatments were needed however, since the 12 patients all attained complete response if they completed the regimen.

As part of the NEJM Group’s coverage of ASCO, Christine Sadlowski interviewed the study’s first author, Dr. Andrea Cercek of Memorial Sloan Kettering Cancer Centern about the study and its implications.

The study as published in the New England Journal of Medicine

The post Podcast 294: PD-1 blockade in locally advanced rectal cancer first appeared on Clinical Conversations.

31 episodi

#Fitness #NEJM Group #Science #Biology #Medicine #On Covid19